Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study

Abstract Introduction In the DELIVER study, eptinezumab reduced monthly migraine days (MMDs) more than placebo in patients with 2–4 prior preventive migraine treatment failures. This post hoc analysis evaluated the efficacy of eptinezumab across the 24-week placebo-controlled period of the DELIVER s...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Patricia Pozo-Rosich, Messoud Ashina, Stewart J. Tepper, Sidsel Jensen, Line Pickering Boserup, Mette Krog Josiassen, Bjørn Sperling
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Adis, Springer Healthcare 2024-01-01
Σειρά:	Neurology and Therapy
Θέματα:	Anti-CGRP Eptinezumab Migraine Preventive treatment
Διαθέσιμο Online:	https://doi.org/10.1007/s40120-023-00575-5
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!